S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.26 (+0.13%)
META   486.29 (+0.47%)
GOOGL   136.88 (+0.37%)
AMZN   174.82 (+0.96%)
TSLA   199.78 (-1.12%)
NVDA   790.79 (+1.82%)
NIO   5.62 (+3.50%)
AMD   188.63 (+6.85%)
BABA   74.11 (-0.64%)
T   16.96 (+0.00%)
F   12.37 (+0.57%)
MU   89.46 (-0.28%)
CGC   3.29 (-2.08%)
GE   155.70 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.36 (-12.63%)
PFE   26.70 (-1.26%)
PYPL   60.24 (-0.02%)
XOM   104.61 (+0.28%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.26 (+0.13%)
META   486.29 (+0.47%)
GOOGL   136.88 (+0.37%)
AMZN   174.82 (+0.96%)
TSLA   199.78 (-1.12%)
NVDA   790.79 (+1.82%)
NIO   5.62 (+3.50%)
AMD   188.63 (+6.85%)
BABA   74.11 (-0.64%)
T   16.96 (+0.00%)
F   12.37 (+0.57%)
MU   89.46 (-0.28%)
CGC   3.29 (-2.08%)
GE   155.70 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.36 (-12.63%)
PFE   26.70 (-1.26%)
PYPL   60.24 (-0.02%)
XOM   104.61 (+0.28%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.26 (+0.13%)
META   486.29 (+0.47%)
GOOGL   136.88 (+0.37%)
AMZN   174.82 (+0.96%)
TSLA   199.78 (-1.12%)
NVDA   790.79 (+1.82%)
NIO   5.62 (+3.50%)
AMD   188.63 (+6.85%)
BABA   74.11 (-0.64%)
T   16.96 (+0.00%)
F   12.37 (+0.57%)
MU   89.46 (-0.28%)
CGC   3.29 (-2.08%)
GE   155.70 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.36 (-12.63%)
PFE   26.70 (-1.26%)
PYPL   60.24 (-0.02%)
XOM   104.61 (+0.28%)
S&P 500   5,077.43 (+0.15%)
DOW   38,885.64 (-0.16%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.26 (+0.13%)
META   486.29 (+0.47%)
GOOGL   136.88 (+0.37%)
AMZN   174.82 (+0.96%)
TSLA   199.78 (-1.12%)
NVDA   790.79 (+1.82%)
NIO   5.62 (+3.50%)
AMD   188.63 (+6.85%)
BABA   74.11 (-0.64%)
T   16.96 (+0.00%)
F   12.37 (+0.57%)
MU   89.46 (-0.28%)
CGC   3.29 (-2.08%)
GE   155.70 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.36 (-12.63%)
PFE   26.70 (-1.26%)
PYPL   60.24 (-0.02%)
XOM   104.61 (+0.28%)
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

$423.85
-3.12 (-0.73%)
(As of 12:33 PM ET)
Today's Range
$420.24
$429.18
50-Day Range
$400.63
$446.08
52-Week Range
$283.60
$448.40
Volume
333,126 shs
Average Volume
1.44 million shs
Market Capitalization
$109.48 billion
P/E Ratio
30.51
Dividend Yield
N/A
Price Target
$417.27

Vertex Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.41 Rating Score
Upside/​Downside
1.1% Downside
$417.27 Price Target
Short Interest
Healthy
1.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.69mentions of Vertex Pharmaceuticals in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$7.99 M Sold Last Quarter
Proj. Earnings Growth
9.01%
From $14.98 to $16.33 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

148th out of 958 stocks

Pharmaceutical Preparations Industry

59th out of 450 stocks


VRTX stock logo

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company headquartered in Boston, Massachusetts, was founded in 1989 by Joshua Boger and Kevin J. Kinsella with a vision to revolutionize disease treatments through rational drug design. Their mission is to "transform the way serious diseases are treated," and they have made significant strides in achieving this goal. The company specializes in researching, developing, and commercializing innovative therapies for various medical conditions, primarily focusing on cystic fibrosis. Using cutting-edge science and technology, Vertex has become a leading player in the biotech industry, particularly in the field of precision medicine.

Vertex has overcome challenges and achieved milestones, chronicled in Barry Werth's book "The Billion-Dollar Molecule." Over the years, the company's research and development efforts have primarily targeted viral infections, inflammatory and autoimmune disorders, cancer, and other specialty diseases. Vertex's flagship products are dedicated to treating cystic fibrosis, a genetic condition affecting the respiratory and digestive systems. Notable among these are Kalydeco, the first FDA-approved drug addressing the underlying cause of cystic fibrosis for specific gene mutations, Orkambi, a combination drug for patients with the most common cystic fibrosis mutation (F508del), Symdeko, a dual combination treatment for certain gene mutations and Trikafta, a groundbreaking triple-combination therapy for cystic fibrosis.

The company's target market consists of patients suffering from serious diseases, especially those with cystic fibrosis and other genetic disorders. Vertex's therapies are designed to cater to specific gene mutations, offering personalized and precision medicine approaches. Key customers include patients with cystic fibrosis and their families, healthcare providers specializing in genetic diseases and health systems, and insurers providing access to these life-changing therapies. Vertex Pharmaceuticals has achieved significant financial growth in recent years, reflecting its successful drug development efforts. Impressive revenue metrics and robust earnings metrics indicate the company's ability to translate its research into profitable treatments efficiently. The company's strong profit margin metrics also showcase its effective financial management.

The positive financial performance has driven the company's stock price upwards, reflecting investor confidence in Vertex's ability to deliver innovative therapies and capitalize on unmet medical needs. The company's strong financials, expanding product pipeline, and contributions to cystic fibrosis treatment have justified its favorable valuation compared to industry peers. Vertex Pharmaceuticals' successful development and commercialization of Trikafta have been key drivers behind the company's positive valuation and investor sentiment. The drug's significant impact on patients and its potential for continued growth have attracted investors seeking exposure to the dynamic biopharmaceutical sector.

As Vertex explores gene-editing therapies in collaboration with CRISPR Therapeutics and Arbor Biotechnologies, investors view the company as a strategic player in addressing significant unmet medical needs. The company's commitment to research and development further solidifies investor confidence in its long-term prospects.

Vertex Pharmaceuticals has demonstrated resilient stock performance. Investors recognize the company's value as a pioneer in the biotech industry, with a focus on precision medicine and transformative therapies. The company's dedication to research and its successful commercialization of existing drugs underscores its strategic positioning in the market.

As Vertex continues to expand its product pipeline and explore new treatment avenues, investors remain optimistic about the company's growth potential. The company's innovative research collaborations, particularly in gene-editing therapies, are expected to drive further positive investor sentiment. In the broader industry, Vertex Pharmaceuticals is well-positioned relative to its peers. Its specialization in precision medicine and groundbreaking therapies for genetic diseases sets it apart, giving the company a competitive advantage. Vertex's successful track record and commitment to addressing unmet medical needs further reinforce its strong position in the market.

While Vertex Pharmaceuticals has achieved significant milestones, the company faces certain risks and challenges. Regulatory hurdles, competitive pressures, and the need for continued investment in research and development are potential factors that may impact its future growth. However, the company's risk management strategies and prudent financial management are designed to mitigate potential risks and position Vertex for continued success. As the company continues to innovate and expand its product portfolio, it is expected to maintain its strong position in the biopharmaceutical industry.

VRTX Stock Price History

VRTX Stock News Headlines

bluebird bio: How to play LEAPS options for growth and income (VRTX)
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Is CRISPR Therapeutics the NVIDIA of gene editing? (VRTX)
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
Gene therapy: Why does it cost millions for a single treatment? (VRTX)
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
VRTX Jun 2025 380.000 put
VRTX Mar 2024 490.000 call
Vertex Pharmaceuticals (VRTX) Should Remain Supported
3 Biotech Stocks Bound to Blast Off By 2029
2 Stocks That Could Crush the Market in 2024
VRTX Mar 2024 400.000 put
VRTX Mar 2024 415.000 call
Insider Sell: EVP, Chief Technical Ops. Off. ...
3 Secret Stocks to Double Your Money by 2028
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
2/29/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
Employees
5,400
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$417.27
High Stock Price Target
$540.00
Low Stock Price Target
$325.00
Potential Upside/Downside
-1.9%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
22 Analysts

Profitability

Net Income
$3.62 billion
Pretax Margin
44.38%

Debt

Sales & Book Value

Annual Sales
$9.87 billion
Cash Flow
$14.46 per share
Book Value
$68.06 per share

Miscellaneous

Free Float
257,275,000
Market Cap
$109.84 billion
Optionable
Optionable
Beta
0.36

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Wednesday, February 21, 2024 at 2:04 PM.

Pros

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • Vertex Pharmaceuticals has a strong track record of developing and commercializing innovative therapies for treating cystic fibrosis, such as TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI.
  • The company reported impressive quarterly earnings results, beating the consensus estimate and demonstrating a solid return on equity and net margin.
  • Research analysts have set high price targets for Vertex Pharmaceuticals, indicating positive market sentiment and growth potential.
  • Vertex Pharmaceuticals has a diverse portfolio of treatments catering to different mutations of cystic fibrosis, expanding its market reach and revenue streams.
  • Despite recent insider selling activity, Vertex Pharmaceuticals remains a key player in the biotechnology sector with a strong financial position.

Cons

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Vertex Pharmaceuticals faces competition in the biotechnology industry, which could impact its market share and pricing power.
  • The stock price of Vertex Pharmaceuticals may be influenced by regulatory challenges, clinical trial outcomes, and changes in healthcare policies.
  • There is a risk associated with investing in biotechnology companies due to the uncertainty of drug development success and market acceptance.
  • Vertex Pharmaceuticals' revenue growth may be subject to fluctuations based on patent expirations, generic competition, and pricing pressures.
  • Investors should carefully monitor any developments related to Vertex Pharmaceuticals' pipeline, regulatory approvals, and market dynamics to make informed investment decisions.














VRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 3 sell ratings, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRTX, but not buy additional shares or sell existing shares.
View VRTX analyst ratings
or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price target for 2024?

22 Wall Street research analysts have issued 1 year target prices for Vertex Pharmaceuticals' stock. Their VRTX share price targets range from $325.00 to $540.00. On average, they anticipate the company's share price to reach $417.27 in the next twelve months. This suggests that the stock has a possible downside of 1.1%.
View analysts price targets for VRTX
or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2024?

Vertex Pharmaceuticals' stock was trading at $406.89 at the beginning of the year. Since then, VRTX shares have increased by 3.7% and is now trading at $421.76.
View the best growth stocks for 2024 here
.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 4,130,000 shares, an increase of 24.8% from the January 31st total of 3,310,000 shares. Based on an average trading volume of 1,480,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.6% of the shares of the company are sold short.
View Vertex Pharmaceuticals' Short Interest
.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our VRTX earnings forecast
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings data on Monday, February, 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts' consensus estimates of $3.85 by $0.35. The pharmaceutical company had revenue of $2.52 billion for the quarter, compared to analysts' expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a trailing twelve-month return on equity of 21.91%. During the same period in the previous year, the business earned $3.33 earnings per share.
Read the conference call transcript
.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.6 billion-$10.8 billion, compared to the consensus revenue estimate of $10.6 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.65%), Capital World Investors (8.46%), Price T Rowe Associates Inc. MD (2.28%), Jennison Associates LLC (1.53%), Massachusetts Financial Services Co. MA (1.41%) and Capital Research Global Investors (1.38%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Ourania Tatsis, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends
.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
This page (NASDAQ:VRTX) was last updated on 2/29/2024 by MarketBeat.com Staff